Compare ASPS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | CING |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | Luxembourg | United States |
| Employees | N/A | 14 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7M | 64.6M |
| IPO Year | 2025 | N/A |
| Metric | ASPS | CING |
|---|---|---|
| Price | $6.76 | $5.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $34.50 |
| AVG Volume (30 Days) | 20.8K | ★ 445.0K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $942,213,000.00 | N/A |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $24.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $3.20 |
| 52 Week High | $15.96 | $11.89 |
| Indicator | ASPS | CING |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 42.33 |
| Support Level | $6.06 | $4.94 |
| Resistance Level | $7.37 | $5.54 |
| Average True Range (ATR) | 0.45 | 0.44 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 55.22 | 48.60 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.